{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T15:40:59Z","timestamp":1784734859134,"version":"3.55.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,1,9]],"date-time":"2021-01-09T00:00:00Z","timestamp":1610150400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,9]],"date-time":"2021-01-09T00:00:00Z","timestamp":1610150400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>First-line treatment of aplastic anemia(AA) and for AA patients ineligible for hematopoietic stem cell transplantation (HSCT) has consisted of antithymocyte globulin (ATG), the calcineurin inhibitor cyclosporine A (CsA), and more recently eltrombopag. However, at our institution, we have successfully substituted another calcineurin inhibitor, tacrolimus, as a part of immunosuppressive threatment (IST) for AA due to more favorable toxicity profile. Since there is limited data on the use of tacrolimus in aplastic anemia, we conducted a retrospective review of twenty patients treated with tacrolimus-based immunosuppressive therapy (IST) as a first- or second-line treatment. The overall response rate was comparable to that of patients treated with CsA (18 patients). However, there were no cutaneous side effects observed in patients receiving tacrolimus, a relatively common finding with CsA use. Our data suggest that tacrolimus-based IST is a potential option in AA and might have a more favorable toxicity profile compared to CsA.<\/jats:p>","DOI":"10.1007\/s00277-021-04401-6","type":"journal-article","created":{"date-parts":[[2021,1,9]],"date-time":"2021-01-09T08:47:11Z","timestamp":1610182031000},"page":"933-939","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Effectiveness and safety of tacrolimus with or without eltrombopag, as a part of immunosuppressive treatment of aplastic anemia in adults: a retrospective case series"],"prefix":"10.1007","volume":"100","author":[{"given":"Anastasia","family":"Martynova","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Chiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"Mert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Hermel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8906-1552","authenticated-orcid":false,"given":"Ilene Ceil","family":"Weitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,9]]},"reference":[{"issue":"16","key":"4401_CR1","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1056\/NEJMoa1613878","volume":"376","author":"DM Townsley","year":"2017","unstructured":"Townsley DM et al (2017) \u201cEltrombopag added to standard immunosuppression for aplastic anemia,\u201d (in eng). N Engl J Med 376(16):1540\u20131550. https:\/\/doi.org\/10.1056\/NEJMoa1613878","journal-title":"N Engl J Med"},{"issue":"5","key":"4401_CR2","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1056\/NEJMoa1103975","volume":"365","author":"P Scheinberg","year":"2011","unstructured":"Scheinberg P, Nunez O, Weinstein B, Biancotto A, Wu CO, Young NS (2011) \u201cHorse versus rabbit antithymocyte globulin in acquired aplastic anemia,\u201d (in eng). N Engl J Med 365(5):430\u2013438. https:\/\/doi.org\/10.1056\/NEJMoa1103975","journal-title":"N Engl J Med"},{"issue":"5","key":"4401_CR3","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1080\/17474086.2017.1313700","volume":"10","author":"PC Boddu","year":"2017","unstructured":"Boddu PC, Kadia TM (2017) \u201cUpdates on the pathophysiology and treatment of aplastic anemia: a comprehensive review,\u201d (in eng). Expert Rev Hematol 10(5):433\u2013448. https:\/\/doi.org\/10.1080\/17474086.2017.1313700","journal-title":"Expert Rev Hematol"},{"issue":"11","key":"4401_CR4","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1182\/blood-2016-08-693481","volume":"129","author":"A Bacigalupo","year":"2017","unstructured":"Bacigalupo A (2017) \u201cHow I treat acquired aplastic anemia,\u201d (in eng). Blood 129(11):1428\u20131436. https:\/\/doi.org\/10.1182\/blood-2016-08-693481","journal-title":"Blood"},{"issue":"1","key":"4401_CR5","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/S0037-1963(00)90034-9","volume":"37","author":"JF Tisdale","year":"2000","unstructured":"Tisdale JF, Dunn DE, Maciejewski J (Jan 2000) Cyclophosphamide and other new agents for the treatment of severe aplastic anemia. (in eng), Semin Hematol 37(1):102\u2013109","journal-title":"(in eng), Semin Hematol"},{"issue":"11","key":"4401_CR6","doi-asserted-by":"publisher","first-page":"e0160421","DOI":"10.1371\/journal.pone.0160421","volume":"11","author":"G Muduma","year":"2016","unstructured":"Muduma G, Saunders R, Odeyemi I, Pollock RF (2016) Systematic review and meta-analysis of tacrolimus versus ciclosporin as primary immunosuppression after liver transplant. (in eng), PLoS One 11(11):e0160421. https:\/\/doi.org\/10.1371\/journal.pone.0160421","journal-title":"(in eng), PLoS One"},{"issue":"12","key":"4401_CR7","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1007\/s00228-010-0902-6","volume":"66","author":"L Penninga","year":"2010","unstructured":"Penninga L, M\u00f8ller CH, Gustafsson F, Steinbr\u00fcchel DA, Gluud C (Dec 2010) Tacrolimus versus cyclosporine as primary immunosuppression after heart transplantation: systematic review with meta-analyses and trial sequential analyses of randomised trials. (in eng), Eur J Clin Pharmacol 66(12):1177\u20131187. https:\/\/doi.org\/10.1007\/s00228-010-0902-6","journal-title":"(in eng), Eur J Clin Pharmacol"},{"key":"4401_CR8","doi-asserted-by":"publisher","unstructured":"Penninga L, Wettergren A, Chan AW, Steinbr\u00fcchel DA, Gluud C (2012) Calcineurin inhibitor minimisation versus continuation of calcineurin inhibitor treatment for liver transplant recipients. (in eng), Cochrane Database Syst Rev (3):CD008852. https:\/\/doi.org\/10.1002\/14651858.CD008852.pub2","DOI":"10.1002\/14651858.CD008852.pub2"},{"key":"4401_CR9","doi-asserted-by":"publisher","unstructured":"Penninga L, Penninga EI, M\u00f8ller CH, Iversen M, Steinbr\u00fcchel DA, Gluud C (2013) Tacrolimus versus cyclosporin as primary immunosuppression for lung transplant recipients. (in eng), Cochrane Database Syst Rev (5):CD008817. https:\/\/doi.org\/10.1002\/14651858.CD008817.pub2","DOI":"10.1002\/14651858.CD008817.pub2"},{"issue":"7520","key":"4401_CR10","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1136\/bmj.38569.471007.AE","volume":"331","author":"AC Webster","year":"2005","unstructured":"Webster AC, Woodroffe RC, Taylor RS, Chapman JR, Craig JC (2005) Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: meta-analysis and meta-regression of randomised trial data. (in eng), BMJ 331(7520):810. https:\/\/doi.org\/10.1136\/bmj.38569.471007.AE","journal-title":"(in eng), BMJ"},{"issue":"10","key":"4401_CR11","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1016\/j.bbmt.2015.05.023","volume":"21","author":"Y Inamoto","year":"2015","unstructured":"Inamoto Y, Flowers MED, Wang T, Urbano-Ispizua A, Hemmer MT, Cutler CS, Couriel DR, Alousi AM, Antin JH, Gale RP, Gupta V, Hamilton BK, Kharfan-Dabaja MA, Marks DI, Ringd\u00e9n OTH, Soci\u00e9 G, Solh MM, Akpek G, Cairo MS, Chao NJ, Hayashi RJ, Nishihori T, Reshef R, Saad A, Shah A, Teshima T, Tallman MS, Wirk B, Spellman SR, Arora M, Martin PJ (2015) Tacrolimus versus cyclosporine after hematopoietic cell transplantation for acquired aplastic anemia. (in eng), Biol Blood Marrow Transplant 21(10):1776\u20131782. https:\/\/doi.org\/10.1016\/j.bbmt.2015.05.023","journal-title":"(in eng), Biol Blood Marrow Transplant"},{"key":"4401_CR12","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/j.1749-6632.1993.tb17137.x","volume":"696","author":"G Wiederrecht","year":"1993","unstructured":"Wiederrecht G, Lam E, Hung S, Martin M, Sigal N (Nov 1993) \u201cThe mechanism of action of FK-506 and cyclosporin A,\u201d (in eng). Ann N Y Acad Sci 696:9\u201319","journal-title":"Ann N Y Acad Sci"},{"key":"4401_CR13","doi-asserted-by":"publisher","first-page":"701464","DOI":"10.1155\/2009\/701464","volume":"2009","author":"S Mukherjee","year":"2009","unstructured":"Mukherjee S, Mukherjee U (2009) \u201cA comprehensive review of immunosuppression used for liver transplantation,\u201d (in eng). J Transp Secur 2009:701464\u2013701420. https:\/\/doi.org\/10.1155\/2009\/701464","journal-title":"J Transp Secur"},{"issue":"5","key":"4401_CR14","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1002\/pbc.21926","volume":"52","author":"A Alsultan","year":"2009","unstructured":"Alsultan A, Goldenberg NA, Kaiser N, Graham DK, Hays T (2009) Tacrolimus as an alternative to cyclosporine in the maintenance phase of immunosuppressive therapy for severe aplastic anemia in children. (in eng), Pediatr Blood Cancer 52(5):626\u2013630. https:\/\/doi.org\/10.1002\/pbc.21926","journal-title":"(in eng), Pediatr Blood Cancer"},{"issue":"4","key":"4401_CR15","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1002\/pbc.21751","volume":"52","author":"C Macartney","year":"2009","unstructured":"Macartney C, Freilich M, Odame I, Charpentier K, Dror Y (2009) Complete response to tacrolimus in a child with severe aplastic anemia resistant to cyclosporin A. (in eng), Pediatr Blood Cancer 52(4):525\u2013527. https:\/\/doi.org\/10.1002\/pbc.21751","journal-title":"(in eng), Pediatr Blood Cancer"},{"issue":"3","key":"4401_CR16","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.bcmd.2014.04.008","volume":"53","author":"X Zhu","year":"2014","unstructured":"Zhu X, Guan J, Xu J, Wei J, Jiang L, Yin J, Zhao L, Zhang Y (2014) Pilot study using tacrolimus rather than cyclosporine plus antithymocyte globulin as an immunosuppressive therapy regimen option for severe aplastic anemia in adults. (in eng), Blood Cells Mol Dis 53(3):157\u2013160. https:\/\/doi.org\/10.1016\/j.bcmd.2014.04.008","journal-title":"(in eng), Blood Cells Mol Dis"},{"issue":"23","key":"4401_CR17","doi-asserted-by":"publisher","first-page":"5391","DOI":"10.1182\/blood-2012-02-407684","volume":"119","author":"JC Marsh","year":"2012","unstructured":"Marsh JC, Bacigalupo A, Schrezenmeier H, Tichelli A, Risitano AM, Passweg JR, Killick SB, Warren AJ, Foukaneli T, Aljurf M, al-Zahrani HA, H\u00f6chsmann B, Schafhausen P, Roth A, Franzke A, Brummendorf TH, Dufour C, Oneto R, Sedgwick P, Barrois A, Kordasti S, Elebute MO, Mufti GJ, Socie G, European Blood and Marrow Transplant Group Severe Aplastic Anaemia Working Party (2012) Prospective study of rabbit antithymocyte globulin and cyclosporine for aplastic anemia from the EBMT severe aplastic anaemia working party. (in eng), Blood 119(23):5391\u20135396. https:\/\/doi.org\/10.1182\/blood-2012-02-407684","journal-title":"(in eng), Blood"},{"issue":"6","key":"4401_CR18","doi-asserted-by":"publisher","first-page":"OC15","DOI":"10.7860\/JCDR\/2016\/16144.7952","volume":"10","author":"M Shetty","year":"2016","unstructured":"Shetty M, Narendra AM, Adiraju KP, Modugu NR (2016) Study of aplastic anaemia with cyclosporine in resource poor setting. (in eng), J Clin Diagn Res 10(6):OC15\u2013OC18. https:\/\/doi.org\/10.7860\/JCDR\/2016\/16144.7952","journal-title":"(in eng), J Clin Diagn Res"},{"issue":"10","key":"4401_CR19","first-page":"2540","volume":"79","author":"E Gluckman","year":"1992","unstructured":"Gluckman E et al (1992) Multicenter randomized study comparing cyclosporine-A alone and antithymocyte globulin with prednisone for treatment of severe aplastic anemia. (in eng), Blood 79(10):2540\u20132546","journal-title":"(in eng), Blood"},{"issue":"11","key":"4401_CR20","doi-asserted-by":"publisher","first-page":"2782","DOI":"10.1111\/ajt.14337","volume":"17","author":"M Ilyas","year":"2017","unstructured":"Ilyas M, Colegio OR, Kaplan B, Sharma A (2017) Cutaneous toxicities from transplantation-related medications. (in eng), Am J Transplant 17(11):2782\u20132789. https:\/\/doi.org\/10.1111\/ajt.14337","journal-title":"(in eng), Am J Transplant"},{"issue":"8","key":"4401_CR21","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1097\/TP.0000000000001243","volume":"100","author":"BJ Nankivell","year":"2016","unstructured":"Nankivell BJ, P\u02bcNg CH, O\u02bcConnell PJ, Chapman JR (2016) Calcineurin inhibitor nephrotoxicity through the lens of longitudinal histology: comparison of cyclosporine and tacrolimus eras. (in eng), Transplantation 100(8):1723\u20131731. https:\/\/doi.org\/10.1097\/TP.0000000000001243","journal-title":"(in eng), Transplantation"},{"issue":"2","key":"4401_CR22","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1111\/bjh.13853","volume":"172","author":"SB Killick","year":"2016","unstructured":"Killick SB, Bown N, Cavenagh J, Dokal I, Foukaneli T, Hill A, Hillmen P, Ireland R, Kulasekararaj A, Mufti G, Snowden JA, Samarasinghe S, Wood A, Marsh JCW, the British Society for Standards in Haematology (2016) Guidelines for the diagnosis and management of adult aplastic anaemia. (in eng), Br J Haematol 172(2):187\u2013207. https:\/\/doi.org\/10.1111\/bjh.13853","journal-title":"(in eng), Br J Haematol"},{"issue":"1","key":"4401_CR23","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1200931","volume":"367","author":"MJ Olnes","year":"2012","unstructured":"Olnes MJ, Scheinberg P, Calvo KR, Desmond R, Tang Y, Dumitriu B, Parikh AR, Soto S, Biancotto A, Feng X, Lozier J, Wu CO, Young NS, Dunbar CE (2012) Eltrombopag and improved hematopoiesis in refractory aplastic anemia. (in eng), N Engl J Med 367(1):11\u201319. https:\/\/doi.org\/10.1056\/NEJMoa1200931","journal-title":"(in eng), N Engl J Med"},{"key":"4401_CR24","volume-title":"Blood : Journal of the American Society of Hematology","author":"V Chiu","year":"2017","unstructured":"Chiu V, Weitz IC, Hermel DJ (2017) Tacrolimus is effective immunosuppressive therapy in aplastic anemia. In: Blood : Journal of the American Society of Hematology, vol 130, ed."},{"issue":"8","key":"4401_CR25","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1007\/s00277-019-03658-2","volume":"98","author":"H Cheng","year":"2019","unstructured":"Cheng H, Wang X, Zhou D, Cao J, Larochelle A, Xu KL (2019) Eltrombopag combined with cyclosporine may have an effect on very severe aplastic anemia. (in eng), Ann Hematol 98(8):2009\u20132011. https:\/\/doi.org\/10.1007\/s00277-019-03658-2","journal-title":"(in eng), Ann Hematol"},{"issue":"1","key":"4401_CR26","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1182\/asheducation-2018.1.450","volume":"2018","author":"P Scheinberg","year":"2018","unstructured":"Scheinberg P (2018) Activity of eltrombopag in severe aplastic anemia. (in eng), Hematology Am Soc Hematol Educ Program 2018(1):450\u2013456. https:\/\/doi.org\/10.1182\/asheducation-2018.1.450","journal-title":"(in eng), Hematology Am Soc Hematol Educ Program"},{"issue":"9","key":"4401_CR27","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.3324\/haematol.2008.002642","volume":"94","author":"E Maluf","year":"2009","unstructured":"Maluf E, Hamerschlak N, Cavalcanti AB, Junior AA, Eluf-Neto J, Falcao RP, Lorand-Metze IG, Goldenberg D, Santana CL, de Oliveira Werneck Rodrigues D, Passos LNM, Rosenfeld LGM, Pitta M, Loggetto S, Feitosa Ribeiro AA, Velloso ED, Kondo AT, de Miranda Coelho EO, Pintao MCT, de Souza HM, Borbolla JR, Pasquini R (2009) Incidence and risk factors of aplastic anemia in Latin American countries: the LATIN case-control study. (in eng), Haematologica 94(9):1220\u20131226. https:\/\/doi.org\/10.3324\/haematol.2008.002642","journal-title":"(in eng), Haematologica"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-021-04401-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-021-04401-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-021-04401-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,15]],"date-time":"2021-03-15T09:43:08Z","timestamp":1615801388000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-021-04401-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,9]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["4401"],"URL":"https:\/\/doi.org\/10.1007\/s00277-021-04401-6","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,9]]},"assertion":[{"value":"28 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}